# A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

> **NCT06570369** · PHASE1 · RECRUITING · sponsor: **Sirtsei Pharmaceuticals, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Major Depressive Disorder
- Depression
- Healthy

## Interventions

- **DRUG:** SP-624
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06570369
- **Lead sponsor:** Sirtsei Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06570369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06570369, "A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06570369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*